Recital 7, Regulation (EU) 2026/1806

In forcesince 24 Jul 2026

On 16 April 2026, the Committee for Veterinary Medicinal Products (‘CVMP’) concluded that no further MRL assessment is necessary and that the substance can be included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 with a ‘No MRL required’ classification [Recombinant equine Chorionic Gonadotropin (reCG): Summary of assessment. (EMA/CVMP/5612/2026-16 April 2026): https://www.ema.europa.eu/en/documents/mrl-summary/recombinant-equine-chorionic-gonadotropin-recg-summary-assessment_en.pdf.].